{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:04:57Z","timestamp":1793109897367,"version":"4.5.0"},"reference-count":199,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["R01 AR083110"],"award-info":[{"award-number":["R01 AR083110"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jid.2024.09.023","type":"journal-article","created":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T07:29:25Z","timestamp":1735025365000},"page":"1305-1322","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Insights into the Pathogenesis of Pyoderma Gangrenosum"],"prefix":"10.1016","volume":"145","author":[{"given":"Sarah L.","family":"Becker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Vague","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex G.","family":"Ortega-Loayza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2024.09.023_bib1","first-page":"419","article-title":"Immunoreactivity to dermal vessels in a patient with pyoderma gandrenosum","volume":"5","author":"Abreu Velez","year":"2014","journal-title":"Our Dermatol Online"},{"key":"10.1016\/j.jid.2024.09.023_bib2","doi-asserted-by":"crossref","first-page":"70","DOI":"10.7326\/L15-5107","article-title":"Anakinra improves pyoderma gangrenosum in psoriatic arthritis: a case report","volume":"163","author":"Acquitter","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jid.2024.09.023_bib3","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1046\/j.1523-1747.1998.00311.x","article-title":"Aberrant neutrophil trafficking and metabolic oscillations in severe pyoderma gangrenosum","volume":"111","author":"Adachi","year":"1998","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib4","first-page":"515","article-title":"Interleukin 17 levels are increased in juvenile idiopathic arthritis synovial fluid and induce synovial fibroblasts to produce proinflammatory cytokines and matrix metalloproteinases","volume":"35","author":"Agarwal","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jid.2024.09.023_bib5","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13221","article-title":"Pyoderma gangrenosum adverse event with rituximab use: a postmarketing pharmacovigilance analysis","volume":"33","author":"Aggarwal","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jid.2024.09.023_bib6","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.2174\/138161212799504731","article-title":"Inflammation-induced thrombosis: mechanisms, disease associations and management","volume":"18","author":"Aksu","year":"2012","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jid.2024.09.023_bib7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/md.0b013e18064f9f3","article-title":"Aseptic abscesses: a study of 30 patients with or without inflammatory bowel disease and review of the literature","volume":"86","author":"Andr\u00e9","year":"2007","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jid.2024.09.023_bib8","first-page":"429","article-title":"Phase I\/IIa study of low dose subcutaneous interleukin-2 (IL-2) for treatment of refractory chronic graft versus host disease","volume":"70","author":"Asano","year":"2016","journal-title":"Acta Med Okayama"},{"key":"10.1016\/j.jid.2024.09.023_bib9","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1046\/j.1365-2133.1998.02567.x","article-title":"Pyoderma gangrenosum in a child with congenital partial deficiency of leucocyte adherence glycoproteins","volume":"139","author":"Bedlow","year":"1998","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib10","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1159\/000519320","article-title":"Pyoderma gangrenosum and interleukin inhibitors: a semi-systematic review","volume":"238","author":"Ben Abdallah","year":"2022","journal-title":"Dermatology"},{"key":"10.1016\/j.jid.2024.09.023_bib11","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1365-2133.1982.tb11684.x","article-title":"Pharmacological modulation of neutrophil phagocytic function in a patient with recurrent sepsis, pyoderma gangrenosum and impaired phagocytosis","volume":"106","author":"Bentley-Phillips","year":"1982","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib12","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/imm.13392","article-title":"Neutrophils in pregnancy: new insights into innate and adaptive immune regulation","volume":"164","author":"Bert","year":"2021","journal-title":"Immunology"},{"key":"10.1016\/j.jid.2024.09.023_bib13","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/RHU.0000000000000511","article-title":"Successful treatment of autoimmune disease-associated pyoderma gangrenosum with the IL-1 receptor antagonist anakinra: a case series of 3 patients","volume":"23","author":"Beynon","year":"2017","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.jid.2024.09.023_bib14","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1111\/j.1365-2133.2011.10565.x","article-title":"Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients","volume":"165","author":"Binus","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib15","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/cei.12761","article-title":"Distinct expression of interleukin (IL)-36\u03b1, \u03b2 and \u03b3, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn\u2019s disease","volume":"184","author":"Boutet","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jid.2024.09.023_bib16","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.jaad.2015.06.021","article-title":"Pathophysiology of pyoderma gangrenosum (PG): an updated review","volume":"73","author":"Braswell","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib17","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jaad.2010.12.025","article-title":"Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)--a new autoinflammatory syndrome distinct from PAPA syndrome","volume":"66","author":"Braun-Falco","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib18","first-page":"1","article-title":"Nouvelle contribution a l\u2019etude du phagedenisme geometrique","volume":"6","author":"Brocq","year":"1916","journal-title":"Ann Dermatol Syphiligr"},{"key":"10.1016\/j.jid.2024.09.023_bib19","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1136\/gut.2005.074815","article-title":"Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial","volume":"55","author":"Brooklyn","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.jid.2024.09.023_bib20","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1111\/j.1365-2133.2007.08211.x","article-title":"T-cell receptor repertoire in pyoderma gangrenosum: evidence for clonal expansions and trafficking","volume":"157","author":"Brooklyn","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib21","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1001\/archderm.1930.01440160053009","article-title":"Pyoderma (echthyma) gangrenosum: clinical and experimental observations in five cases occurring in adults","volume":"22","author":"Brunsting","year":"1930","journal-title":"Arch Derm Syphilol"},{"key":"10.1016\/j.jid.2024.09.023_bib22","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1111\/iwj.13359","article-title":"Successful treatment of a refractory pyoderma gangrenosum with risankizumab","volume":"17","author":"Burgdorf","year":"2020","journal-title":"Int Wound J"},{"key":"10.1016\/j.jid.2024.09.023_bib23","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav5908","article-title":"Neutrophil extracellular traps, B cells, and type I interferons contribute to immune dysregulation in hidradenitis suppurativa","volume":"11","author":"Byrd","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jid.2024.09.023_bib24","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1182\/blood-2010-05-283564","article-title":"Complement alternative pathway acts as a positive feedback amplification of neutrophil activation","volume":"117","author":"Camous","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jid.2024.09.023_bib25","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/bjd.13670","article-title":"The Treg\/Th17 cell ratio is reduced in the skin lesions of patients with pyoderma gangrenosum","volume":"173","author":"Caproni","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib26","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.jid.2021.07.187","article-title":"Autoantibodies present in hidradenitis suppurativa correlate with disease severity and promote the release of proinflammatory cytokines in macrophages","volume":"142","author":"Carmona-Rivera","year":"2022","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib27","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/ijd.16676","article-title":"JAK inhibitors: a novel, safe, and efficacious therapy for pyoderma gangrenosum","volume":"62","author":"Castro","year":"2023","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib28","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S0190-9622(83)70191-X","article-title":"Neutrophilic dermatosis of myeloproliferative disorders. Atypical forms of pyoderma gangrenosum and Sweet\u2019s syndrome associated with myeloproliferative disorders","volume":"9","author":"Caughman","year":"1983","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib29","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00277-021-04524-w","article-title":"Ixazomib as treatment for pyoderma gangrenosum associated with IgA smoldering multiple myeloma","volume":"101","author":"Cespedes","year":"2022","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jid.2024.09.023_bib30","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1177\/1933719108329095","article-title":"Inflammation and pregnancy","volume":"16","author":"Challis","year":"2009","journal-title":"Reprod Sci"},{"key":"10.1016\/j.jid.2024.09.023_bib31","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.celrep.2014.06.028","article-title":"The neutrophil NLRC4 inflammasome selectively promotes IL-1\u03b2 maturation without pyroptosis during acute Salmonella challenge","volume":"8","author":"Chen","year":"2014","journal-title":"Cell Rep"},{"key":"10.1016\/j.jid.2024.09.023_bib32","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.mce.2010.04.005","article-title":"The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights","volume":"335","author":"Coutinho","year":"2011","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.jid.2024.09.023_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002098","article-title":"A role for the chemokine RANTES in regulating CD8 T cell responses during chronic viral infection","volume":"7","author":"Crawford","year":"2011","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.jid.2024.09.023_bib34","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1111\/exd.14397","article-title":"Evaluation of neutrophil extracellular trap deregulated formation in pyoderma gangrenosum","volume":"30","author":"Croia","year":"2021","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib35","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2016.07.019","article-title":"The deubiquitinase OTULIN is an essential negative regulator of inflammation and autoimmunity","volume":"166","author":"Damgaard","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.jid.2024.09.023_bib36","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41423-018-0024-0","article-title":"NETosis, complement, and coagulation: a triangular relationship","volume":"16","author":"de Bont","year":"2019","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.jid.2024.09.023_bib37","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1111\/bjd.13493","article-title":"The genetics of pyoderma gangrenosum and implications for treatment: a systematic review","volume":"172","author":"Defilippis","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib38","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1002\/art.34332","article-title":"Brief report: genotype, phenotype, and clinical course in five patients with PAPA syndrome (pyogenic sterile arthritis, pyoderma gangrenosum, and acne)","volume":"64","author":"Demidowich","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jid.2024.09.023_bib39","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ad.2011.04.014","volume":"103","author":"D\u00edaz-Corpas","year":"2012","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.jid.2024.09.023_bib40","first-page":"1058","article-title":"Efficacy of systemic dapsone treatment for pyoderma gangrenosum: a retrospective review","volume":"17","author":"Din","year":"2018","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib41","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s40265-023-01931-3","article-title":"Pyoderma gangrenosum: treatment options","volume":"83","author":"Dissemond","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.jid.2024.09.023_bib42","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-15412-7","article-title":"The NOD2 receptor is crucial for immune responses towards New World Leishmania species","volume":"7","author":"dos Santos","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jid.2024.09.023_bib43","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/bjd.13668","article-title":"First nicastrin mutation in PASH (pyoderma gangrenosum, acne and suppurative hidradenitis) syndrome","volume":"173","author":"Duchatelet","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib44","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/cr.2009.139","article-title":"Complement and its role in innate and adaptive immune responses","volume":"20","author":"Dunkelberger","year":"2010","journal-title":"Cell Res"},{"key":"10.1016\/j.jid.2024.09.023_bib45","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1136\/gut.37.4.585","article-title":"\u2018Sticky\u2019 neutrophils, pathergic arthritis, and response to heparin in pyoderma gangrenosum complicating ulcerative colitis","volume":"37","author":"Dwarakanath","year":"1995","journal-title":"Gut"},{"key":"10.1016\/j.jid.2024.09.023_bib46","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/exd.14360","article-title":"Characterizing the presence of neutrophil extracellular traps in neutrophilic dermatoses","volume":"30","author":"Eid","year":"2021","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib47","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12959-015-0047-z","article-title":"Thrombosis in vasculitis: from pathogenesis to treatment","volume":"13","author":"Emmi","year":"2015","journal-title":"Thromb J"},{"key":"10.1016\/j.jid.2024.09.023_bib48","article-title":"Pathergy phenomenon","volume":"8","author":"Ergun","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jid.2024.09.023_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.673453","article-title":"Case report: a novel mutation in NFKB1 associated with pyoderma gangrenosum","volume":"12","author":"Fang","year":"2021","journal-title":"Front Genet"},{"key":"10.1016\/j.jid.2024.09.023_bib50","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3389\/fphar.2017.00278","article-title":"Potential of IL-1, IL-18 and inflammasome inhibition for the treatment of inflammatory skin diseases","volume":"8","author":"Fenini","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jid.2024.09.023_bib51","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/exd.14534","article-title":"Pyoderma gangrenosum: a systematic review of the molecular characteristics of disease","volume":"31","author":"Flora","year":"2022","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib52","doi-asserted-by":"crossref","first-page":"6053","DOI":"10.4049\/jimmunol.1301481","article-title":"IL-36 promotes myeloid cell infiltration, activation, and inflammatory activity in skin","volume":"192","author":"Foster","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.jid.2024.09.023_bib53","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/j.1365-2133.2004.06249.x","article-title":"Leukocytapheresis treatment for pyoderma gangrenosum","volume":"151","author":"Fujimoto","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib54","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nri3707","article-title":"The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing","volume":"14","author":"Gaffen","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jid.2024.09.023_bib55","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.dld.2005.02.011","article-title":"Expression of matrix metalloproteinases-2 and -9 in intestinal tissue of patients with inflammatory bowel diseases","volume":"37","author":"Gao","year":"2005","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jid.2024.09.023_bib56","article-title":"The anaphylatoxin C5a: structure, function, signaling, physiology, disease, and therapeutics [published correction appears in Int Immunopharmacol 2023;125:111089]","volume":"118","author":"Ghosh","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jid.2024.09.023_bib57","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.210.Supp.149.12","article-title":"Human OTULIN mutations can cause distinct inflammatory disease phenotypes depending on the protein domain that is mutated","volume":"210","author":"Gil","year":"2023","journal-title":"J Immunol"},{"key":"10.1016\/j.jid.2024.09.023_bib58","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1001\/archderm.1956.01550110087017","article-title":"Pyoderma gangrenosum; report of a case controlled by cortisone","volume":"74","author":"Greco","year":"1956","journal-title":"AMA Arch Derm"},{"key":"10.1016\/j.jid.2024.09.023_bib59","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jdcr.2023.01.022","article-title":"Spesolimab use in treatment of pyoderma gangrenosum","volume":"34","author":"Gu\u00e9nin","year":"2023","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jid.2024.09.023_bib60","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11037","article-title":"Coagulation induced by C3aR-dependent NETosis drives protumorigenic neutrophils during small intestinal tumorigenesis","volume":"7","author":"Guglietta","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.jid.2024.09.023_bib61","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jid.2020.04.019","article-title":"Comparison of three diagnostic frameworks for pyoderma gangrenosum","volume":"141","author":"Haag","year":"2021","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib62","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1080\/09546634.2019.1606888","article-title":"Clinical factors influencing the response to intravenous immunoglobulin treatment in cases of treatment-resistant pyoderma gangrenosum","volume":"31","author":"Haag","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jid.2024.09.023_bib63","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00403-024-02829-0","article-title":"An approach to diagnosis and management of patients with pyoderma gangrenosum from an international perspective: results from an expert forum","volume":"316","author":"Haddadin","year":"2024","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jid.2024.09.023_bib64","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1346-8138.2010.01009.x","article-title":"Clinical implications of leukocytapheresis using a centrifugal cell separator for steroid-resistant pyoderma gangrenosum associated with inflammatory bowel disease","volume":"38","author":"Hanafusa","year":"2011","journal-title":"J Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib65","doi-asserted-by":"crossref","first-page":"6318","DOI":"10.1016\/S0021-9258(19)39328-7","article-title":"Processing of precursor interleukin 1 beta and inflammatory disease","volume":"265","author":"Hazuda","year":"1990","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jid.2024.09.023_bib66","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.celrep.2015.12.072","article-title":"Neutrophil-derived proteases escalate inflammation through activation of IL-36 family cytokines","volume":"14","author":"Henry","year":"2016","journal-title":"Cell Rep"},{"key":"10.1016\/j.jid.2024.09.023_bib67","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/bjd.16019","article-title":"Interleukin-36 in hidradenitis suppurativa: evidence for a distinctive proinflammatory role and a key factor in the development of an inflammatory loop","volume":"178","author":"Hessam","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib68","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/0738-081X(83)90045-7","article-title":"Pyoderma gangrenosum","volume":"1","author":"Hickman","year":"1983","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib69","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14736","article-title":"Treatment of pyoderma gangrenosum: a multicenter survey-based study assessing satisfaction and quality of life","volume":"34","author":"Hobbs","year":"2021","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jid.2024.09.023_bib70","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1001\/archdermatol.2010.328","article-title":"Hidradenitis suppurativa and concomitant pyoderma gangrenosum: a case series and literature review","volume":"146","author":"Hsiao","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib71","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/bjd.17347","article-title":"Pyoderma gangrenosum and its impact on quality of life: a multicentre, prospective study","volume":"180","author":"Ighani","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib72","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jaci.2019.01.042","article-title":"IL-4 receptor engagement in human neutrophils impairs their migration and extracellular trap formation","volume":"144","author":"Impellizzieri","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2024.09.023_bib73","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1148893","article-title":"A novel murine model of pyoderma gangrenosum reveals that inflammatory skin-gut crosstalk is mediated by IL-1\u03b2-primed neutrophils","volume":"14","author":"Jatana","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2024.09.023_bib74","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20193266","article-title":"Koebner phenomenon leading to the formation of new psoriatic lesions: evidences and mechanisms","volume":"39","author":"Ji","year":"2019","journal-title":"Biosci Rep"},{"key":"10.1016\/j.jid.2024.09.023_bib75","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1111\/1346-8138.14611","article-title":"Pyoderma gangrenosum triggered by switching from adalimumab to secukinumab","volume":"46","author":"Jin","year":"2019","journal-title":"J Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib76","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jaci.2016.08.056","article-title":"IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis","volume":"140","author":"Johnston","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2024.09.023_bib77","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1440-1746.1993.tb01643.x","article-title":"Serum interleukin-8 in inflammatory bowel disease","volume":"8","author":"Jones","year":"1993","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jid.2024.09.023_bib78","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/BOR.0000000000000266","article-title":"Anti-inflammatory panacea? The expanding therapeutics of interleukin-1 blockade","volume":"28","author":"Kahlenberg","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jid.2024.09.023_bib79","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1744-9987.2005.00284.x","article-title":"Treatment of pyoderma gangrenosum with granulocyte and monocyte adsorption apheresis","volume":"9","author":"Kanekura","year":"2005","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.jid.2024.09.023_bib80","doi-asserted-by":"crossref","first-page":"e245","DOI":"10.1111\/1346-8138.17152","article-title":"Serum cytokine profiles in a case of post-cesarean pyoderma gangrenosum","volume":"51","author":"Kikuchi","year":"2024","journal-title":"J Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib81","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.cgh.2018.10.047","article-title":"Tofacitinib for the treatment of pyoderma gangrenosum","volume":"17","author":"Kochar","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jid.2024.09.023_bib82","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1111\/bjd.14037","article-title":"Canakinumab in adults with steroid-refractory pyoderma gangrenosum","volume":"173","author":"Kolios","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib83","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1159\/000481432","article-title":"Clinical disease patterns in a regional Swiss cohort of 34 pyoderma gangrenosum patients","volume":"233","author":"Kolios","year":"2017","journal-title":"Dermatology"},{"key":"10.1016\/j.jid.2024.09.023_bib84","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1056\/NEJMoa1108188","article-title":"Interleukin-2 and regulatory T cells in graft-versus-host disease","volume":"365","author":"Koreth","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jid.2024.09.023_bib85","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.3390\/ijms19092714","article-title":"Peptides as therapeutic agents for inflammatory-related diseases","volume":"19","author":"La Manna","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jid.2024.09.023_bib86","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1038\/jid.2012.130","article-title":"Incidence, mortality, and disease associations of pyoderma gangrenosum in the United Kingdom: a retrospective cohort study","volume":"132","author":"Langan","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib87","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1084\/jem.20041257","article-title":"IL-23 drives a pathogenic T cell population that induces autoimmune inflammation","volume":"201","author":"Langrish","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.jid.2024.09.023_bib88","doi-asserted-by":"crossref","first-page":"S156","DOI":"10.1016\/j.jid.2021.08.046","article-title":"044 safety and efficacy of anti-IL-17 (secukinumab) for the treatment of pyoderma gangrenosum","volume":"141","author":"Lauffer","year":"2021","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib89","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1136\/ard-2023-225085","article-title":"Interrupting an IFN-\u03b3-dependent feedback loop in the syndrome of pyogenic arthritis with pyoderma gangrenosum and acne","volume":"83","author":"Lee","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jid.2024.09.023_bib90","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1111\/jdv.13736","article-title":"Use of tocilizumab in a patient with pyoderma gangrenosum and rheumatoid arthritis","volume":"31","author":"Lee","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2024.09.023_bib91","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.chom.2019.10.007","article-title":"Toxin-triggered interleukin-1 receptor signaling enables early-life discrimination of pathogenic versus commensal skin bacteria","volume":"26","author":"Leech","year":"2019","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.jid.2024.09.023_bib92","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.4049\/jimmunol.1102404","article-title":"Neutrophil extracellular traps that are not degraded in systemic lupus erythematosus activate complement exacerbating the disease","volume":"188","author":"Leffler","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.jid.2024.09.023_bib93","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ebiom.2016.03.015","article-title":"Plasmin as a complement C5 convertase","volume":"5","author":"Leung","year":"2016","journal-title":"EBiomedicine"},{"key":"10.1016\/j.jid.2024.09.023_bib94","doi-asserted-by":"crossref","first-page":"E41","DOI":"10.1002\/ibd.21684","article-title":"Failure of anakinra treatment of pyoderma gangrenosum in an IBD patient and relevance to the PSTPIP1 gene","volume":"17","author":"Lin","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jid.2024.09.023_bib95","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1093\/ced\/llad317","article-title":"Rapid response to spesolimab in a patient with severe refractory pyoderma gangrenosum","volume":"49","author":"Ma","year":"2023","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib96","doi-asserted-by":"crossref","DOI":"10.1038\/srep24880","article-title":"Neutrophil elastase-mediated proteolysis activates the anti-inflammatory cytokine IL-36 Receptor antagonist","volume":"6","author":"Macleod","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jid.2024.09.023_bib97","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/j.1600-0560.2006.00654.x","article-title":"Clonality in the setting of Sweet\u2019s syndrome and pyoderma gangrenosum is not limited to underlying myeloproliferative disease","volume":"34","author":"Magro","year":"2007","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jid.2024.09.023_bib98","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231911307","article-title":"Coronavirus disease 2019-associated thrombotic microangiopathy: literature review","volume":"23","author":"Malgaj Vre\u010dko","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jid.2024.09.023_bib99","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/eji.201141921","article-title":"The NLRP3\/ASC\/Caspase-1 axis regulates IL-1\u03b2 processing in neutrophils","volume":"42","author":"Mankan","year":"2012","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jid.2024.09.023_bib100","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s40257-022-00699-8","article-title":"Pyoderma gangrenosum: an updated literature review on established and emerging pharmacological treatments","volume":"23","author":"Maronese","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib101","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1097-2765(02)00599-3","article-title":"The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta","volume":"10","author":"Martinon","year":"2002","journal-title":"Mol Cell"},{"key":"10.1016\/j.jid.2024.09.023_bib102","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1365-2249.2010.04201.x","article-title":"Role of inflammatory cells, cytokines and matrix metalloproteinases in neutrophil-mediated skin diseases","volume":"162","author":"Marzano","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jid.2024.09.023_bib103","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1111\/bjd.15226","article-title":"Autoinflammation in pyoderma gangrenosum and its syndromic form (pyoderma gangrenosum, acne and suppurative hidradenitis)","volume":"176","author":"Marzano","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib104","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/cei.12394","article-title":"Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet's syndrome","volume":"178","author":"Marzano","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jid.2024.09.023_bib105","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3109\/09546631003686069","article-title":"Pyoderma gangrenosum: study of 21 patients and proposal of a \u2018clinicotherapeutic\u2019 classification","volume":"22","author":"Marzano","year":"2011","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jid.2024.09.023_bib106","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41572-020-0213-x","article-title":"Pyoderma gangrenosum","volume":"6","author":"Maverakis","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jid.2024.09.023_bib107","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s13671-018-0224-y","article-title":"Pyoderma gangrenosum: what do we know now?","volume":"7","author":"McKenzie","year":"2018","journal-title":"Curr Derm Rep"},{"key":"10.1016\/j.jid.2024.09.023_bib108","series-title":"Pyoderma gangrenosum treated with secukinumab: a case report","volume":"8","author":"McPhie","year":"2020"},{"key":"10.1016\/j.jid.2024.09.023_bib109","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110891","article-title":"Intestinal inflammation alters the antigen-specific immune response to a skin commensal","volume":"39","author":"Merana","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.jid.2024.09.023_bib110","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1182\/blood.2020007008","article-title":"Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome","volume":"136","author":"Middleton","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jid.2024.09.023_bib111","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1136\/annrheumdis-2018-213746","article-title":"Dysregulated neutrophil responses and neutrophil extracellular trap formation and degradation in PAPA syndrome","volume":"77","author":"Mistry","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jid.2024.09.023_bib112","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2340\/00015555-2507","article-title":"Pyoderma gangrenosum, acne and suppurative hidradenitis syndrome treated with granulocyte and monocyte adsorption apheresis","volume":"97","author":"Mizutani","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jid.2024.09.023_bib113","doi-asserted-by":"crossref","first-page":"4227","DOI":"10.1111\/iwj.14323","article-title":"Predilection sites of pyoderma gangrenosum: retrospective study of 170 clearly diagnosed patients","volume":"20","author":"Moelleken","year":"2023","journal-title":"Int Wound J"},{"key":"10.1016\/j.jid.2024.09.023_bib114","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/j.jaad.2019.09.032","article-title":"Pyoderma gangrenosum in hematologic malignancies: a systematic review","volume":"82","author":"Montagnon","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib115","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1038\/s41598-023-31914-z","article-title":"Different molecular pathways are disrupted in Pyoderma gangrenosum patients and are associated with the severity of the disease","volume":"13","author":"Moura","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.jid.2024.09.023_bib116","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12863-021-01001-1","article-title":"Analysis of transcriptomic data sets supports the role of IL-6 in NETosis and immunothrombosis in severe COVID-19","volume":"22","author":"Mukhopadhyay","year":"2021","journal-title":"BMC Genom Data"},{"key":"10.1016\/j.jid.2024.09.023_bib117","first-page":"504","article-title":"Successful therapy for pyoderma gangrenosum with a Janus kinase 2 inhibitor","volume":"179","author":"Nasifoglu","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib118","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1365-4362.1985.tb05359.x","article-title":"Leukocyte chemotaxis and pyoderma gangrenosum","volume":"24","author":"Nerella","year":"1985","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib119","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.ajpath.2010.12.035","article-title":"Alteration in the gene encoding protein tyrosine phosphatase nonreceptor type 6 (PTPN6\/SHP1) may contribute to neutrophilic dermatoses","volume":"178","author":"Nesterovitch","year":"2011","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jid.2024.09.023_bib120","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/j.1365-2230.2011.04137.x","article-title":"Mutations in the PSTPIP1 gene and aberrant splicing variants in patients with pyoderma gangrenosum","volume":"36","author":"Nesterovitch","year":"2011","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib121","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.ajpath.2010.12.053","article-title":"Spontaneous insertion of a b2 element in the ptpn6 gene drives a systemic autoinflammatory disease in mice resembling neutrophilic dermatosis in humans","volume":"178","author":"Nesterovitch","year":"2011","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jid.2024.09.023_bib122","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/labinvest.3780064","article-title":"Interleukin-8 overexpression is present in pyoderma gangrenosum ulcers and leads to ulcer formation in human skin xenografts","volume":"80","author":"Oka","year":"2000","journal-title":"Lab Invest"},{"key":"10.1016\/j.jid.2024.09.023_bib123","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1744-9987.2007.00498.x","article-title":"A case report of steroid and immunosuppressant-resistant pyoderma gangrenosum successfully treated by granulocytapheresis","volume":"11","author":"Okuma","year":"2007","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.jid.2024.09.023_bib124","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s40257-024-00875-y","article-title":"Human inborn errors of immunity in pyoderma gangrenosum: a systematic review","volume":"25","author":"Oprea","year":"2024","journal-title":"Am J Clinc Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib125","doi-asserted-by":"crossref","DOI":"10.1111\/exd.14954","article-title":"What can inherited immunodeficiencies reveal about pyoderma gangrenosum?","volume":"33","author":"Oprea","year":"2024","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib126","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/wrr.13005","article-title":"Pyoderma gangrenosum study pilot registry: the first step to a better understanding","volume":"30","author":"Orfaly","year":"2022","journal-title":"Wound Repair Regen"},{"key":"10.1016\/j.jid.2024.09.023_bib127","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.h2958","article-title":"Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial","volume":"350","author":"Ormerod","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.jid.2024.09.023_bib128","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jid.2021.08.431","article-title":"Molecular and cellular characterization of pyoderma gangrenosum: implications for the use of gene expression","volume":"142","author":"Ortega-Loayza","year":"2022","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib129","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1111\/bjd.15837","article-title":"Dysregulation of inflammatory gene expression in lesional and nonlesional skin of patients with pyoderma gangrenosum","volume":"178","author":"Ortega-Loayza","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib130","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jdcr.2020.06.011","article-title":"Pyoderma gangrenosum induced by secukinumab in a patient with psoriasis successfully treated with ustekinumab","volume":"6","author":"Petty","year":"2020","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jid.2024.09.023_bib131","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/jid.2012.372","article-title":"\u03b3-secretase mutations in hidradenitis suppurativa: new insights into disease pathogenesis","volume":"133","author":"Pink","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib132","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1365-2133.1983.tb03966.x","article-title":"Direct immunofluorescence in pyoderma gangrenosum","volume":"108","author":"Powell","year":"1983","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib133","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1001\/archderm.1983.01650300022009","article-title":"Pyoderma gangrenosum and monoclonal gammopathy","volume":"119","author":"Powell","year":"1983","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib134","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/jdv.13100","article-title":"Phenotypical characterization of circulating cell subsets in pyoderma gangrenosum patients: the experience of the Italian immuno-pathology group","volume":"30","author":"Quaglino","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2024.09.023_bib135","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.4049\/jimmunol.1402354","article-title":"Complement deficiency promotes cutaneous wound healing in mice","volume":"194","author":"Rafail","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.jid.2024.09.023_bib136","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1741-7015-9-1","article-title":"Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage study","volume":"9","author":"Ramagopalan","year":"2011","journal-title":"BMC Med"},{"key":"10.1016\/j.jid.2024.09.023_bib137","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13074","article-title":"Neutrophilic dermatoses as adverse effects of checkpoint inhibitors: a review","volume":"32","author":"Ravi","year":"2019","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jid.2024.09.023_bib138","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jdcr.2021.11.030","article-title":"Modified dose of guselkumab for treatment of pyoderma gangrenosum","volume":"21","author":"Reese","year":"2022","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jid.2024.09.023_bib139","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.4049\/jimmunol.177.7.4794","article-title":"A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation Pathways","volume":"177","author":"Ritis","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.jid.2024.09.023_bib140","first-page":"619","article-title":"Epidermotropism of inflammatory cells differentiates pyoderma gangrenosum from venous leg ulcers","volume":"20","author":"Ronicke","year":"2022","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.jid.2024.09.023_bib141","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.4049\/jimmunol.167.5.2861","article-title":"Human IgA activates the complement system via the mannan-binding lectin pathway","volume":"167","author":"Roos","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.jid.2024.09.023_bib142","doi-asserted-by":"crossref","first-page":"222","DOI":"10.4103\/idoj.IDOJ_153_19","article-title":"Pyoderma gangrenosum over hypertrophic scar: report of a rare presentation","volume":"11","author":"Rout","year":"2020","journal-title":"Indian Dermatol Online J"},{"key":"10.1016\/j.jid.2024.09.023_bib143","doi-asserted-by":"crossref","first-page":"e660","DOI":"10.1111\/jdv.18683","article-title":"The role of interleukins 6, 8, 17 and 23 in the pathogenesis of pyoderma gangrenosum","volume":"37","author":"Rubas","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2024.09.023_bib144","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1074\/jbc.M308809200","article-title":"Functional cooperation between interleukin-17 and tumor necrosis factor-alpha is mediated by CCAAT\/enhancer-binding protein family members","volume":"279","author":"Ruddy","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jid.2024.09.023_bib145","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1684\/ejd.2014.2297","article-title":"Neutrophilic disease of the skin and intestines after ipilimumab treatment for malignant melanoma - simultaneous occurrence of pyoderma gangrenosum and colitis","volume":"24","author":"Rudolph","year":"2014","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib146","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1038\/mi.2015.134","article-title":"IL-36\u03b1 expression is elevated in ulcerative colitis and promotes colonic inflammation","volume":"9","author":"Russell","year":"2016","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.jid.2024.09.023_bib147","article-title":"A case of pyoderma gangrenosum misdiagnosed as necrotizing infection: a potential diagnostic catastrophe","volume":"2018","author":"Saffie","year":"2018","journal-title":"Case Rep Infect Dis"},{"key":"10.1016\/j.jid.2024.09.023_bib148","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1600-0609.2006.00697.x","article-title":"CD30+ anaplastic large cell lymphoma complicated by pyoderma gangrenosum with increased levels of serum cytokines","volume":"77","author":"Saito","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jid.2024.09.023_bib149","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1111\/ajd.14266","article-title":"Switch from adalimumab to Brodalumab as a possible trigger factor for the onset of pyoderma gangrenosum","volume":"65","author":"Salvia","year":"2024","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib150","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.cyto.2012.12.023","article-title":"Cytokine profiles in acute myeloid leukemia patients at diagnosis: survival is inversely correlated with IL-6 and directly correlated with IL-10 levels","volume":"61","author":"Sanchez-Correa","year":"2013","journal-title":"Cytokine"},{"key":"10.1016\/j.jid.2024.09.023_bib151","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2217\/imt.14.106","article-title":"The inflammasome and IL-1\u03b2: implications for the treatment of inflammatory diseases","volume":"7","author":"Satoh","year":"2015","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jid.2024.09.023_bib152","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/1346-8138.17028","article-title":"Genetic mutations in pyoderma gangrenosum, hidradenitis suppurativa, and associated autoinflammatory syndromes: insights into pathogenic mechanisms and shared pathways","volume":"51","author":"Satoh","year":"2024","journal-title":"J Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib153","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1744-9987.2007.00424.x","article-title":"Efficacy of granulocyte and monocyte adsorption apheresis for three cases of refractory pyoderma gangrenosum","volume":"11","author":"Seishima","year":"2007","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.jid.2024.09.023_bib154","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1159\/000536145","article-title":"Mortality and autopsy findings in patients with pyoderma gangrenosum: a multi-institutional series","volume":"240","author":"Shakshouk","year":"2024","journal-title":"Dermatology"},{"key":"10.1016\/j.jid.2024.09.023_bib155","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1053\/j.jfas.2013.07.003","article-title":"Chronic leg ulceration associated with polycythemia vera responding to Ruxolitinib (Jakafi(\u00ae))","volume":"52","author":"Shanmugam","year":"2013","journal-title":"J Foot Ankle Surg"},{"key":"10.1016\/j.jid.2024.09.023_bib156","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/j.jid.2016.03.002","article-title":"Increased Lipocalin-2 contributes to the pathogenesis of psoriasis by modulating neutrophil chemotaxis and cytokine secretion","volume":"136","author":"Shao","year":"2016","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib157","doi-asserted-by":"crossref","first-page":"746","DOI":"10.3389\/fimmu.2019.00746","article-title":"Neutrophil extracellular traps promote inflammatory responses in psoriasis via activating epidermal TLR4\/IL-36R crosstalk","volume":"10","author":"Shao","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2024.09.023_bib158","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/S0955-0674(98)80035-5","article-title":"Matrix metalloproteinase degradation of extracellular matrix: biological consequences","volume":"10","author":"Shapiro","year":"1998","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.jid.2024.09.023_bib159","article-title":"The inflammatory cytokine profile of myelodysplastic syndromes: a meta-analysis","volume":"98","author":"Shi","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jid.2024.09.023_bib160","doi-asserted-by":"crossref","first-page":"13501","DOI":"10.1073\/pnas.2135380100","article-title":"Pyrin binds the PSTPIP1\/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway","volume":"100","author":"Shoham","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jid.2024.09.023_bib161","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1001\/archderm.1976.01630370072023","article-title":"Pyoderma gangrenosum, defective neutrophil chemotaxis, and leukemia","volume":"112","author":"Shore","year":"1976","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib162","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1093\/rheumatology\/keab868","article-title":"Somatic mutations in rheumatological diseases: VEXAS syndrome and beyond","volume":"61","author":"Sikora","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jid.2024.09.023_bib163","article-title":"Pyoderma gangrenosum-like wounds in leukocyte adhesion deficiency: case report and review of literature","volume":"6","author":"Simpson","year":"2018","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"10.1016\/j.jid.2024.09.023_bib164","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1111\/bjd.15740","article-title":"PASH syndrome (pyoderma gangrenosum, acne and hidradenitis suppurativa): a disease with genetic heterogeneity","volume":"178","author":"Sonbol","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib165","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/bjd.15850","article-title":"Intravenous immunoglobulin as adjunct therapy for refractory pyoderma gangrenosum: systematic review of cases and case series","volume":"178","author":"Song","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib166","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/BOR.0b013e32835ad3ca","article-title":"Thrombosis in vasculitis","volume":"25","author":"Springer","year":"2013","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jid.2024.09.023_bib167","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/bjd.14230","article-title":"Pyoderma gangrenosum and pregnancy: an example of abnormal inflammation and challenging treatment [published correction appears in Br J Dermatol 2016;175:227]","volume":"174","author":"Steele","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib168","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13075-023-03259-5","article-title":"PD-1 signaling uncovers a pathogenic subset of T cells in inflammatory arthritis","volume":"26","author":"Straube","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jid.2024.09.023_bib169","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1600-0560.1986.tb00466.x","article-title":"Histopathologic and immunopathologic study of pyoderma gangrenosum","volume":"13","author":"Su","year":"1986","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jid.2024.09.023_bib170","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1111\/jdv.19935","article-title":"The role of interleukin-36 in health and disease states","volume":"38","author":"Sugiura","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2024.09.023_bib171","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jaad.2015.07.031","article-title":"The spectrum of neutrophilic dermatoses associated with monoclonal gammopathy: association with IgA isotype and inflammatory profile","volume":"73","author":"Szalat","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib172","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/j.0906-6705.2003.00088.x","article-title":"Increased E-selectin, IL-8 and IL-10 gene expression in human skin after minimal trauma","volume":"12","author":"Takeuchi","year":"2003","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib173","article-title":"Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation [published correction appears in Front Immunol 2023;14:1282155]","volume":"14","author":"Tang","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2024.09.023_bib174","doi-asserted-by":"crossref","first-page":"158","DOI":"10.4103\/0019-5154.108076","article-title":"Leukocyte adhesion defect type 1 presenting with recurrent pyoderma gangrenosum","volume":"58","author":"Thakur","year":"2013","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib175","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1056\/NEJMoa2209856","article-title":"A phase 2 trial of peresolimab for adults with rheumatoid arthritis","volume":"388","author":"Tuttle","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jid.2024.09.023_bib176","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jdcr.2023.05.016","article-title":"Resolution of therapy-resistant pyoderma gangrenosum with upadacitinib","volume":"37","author":"Van Eycken","year":"2023","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jid.2024.09.023_bib177","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1126\/science.1196284","article-title":"Gamma-secretase gene mutations in familial acne inversa","volume":"330","author":"Wang","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.jid.2024.09.023_bib178","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.3389\/fimmu.2017.01980","article-title":"Classic ulcerative pyoderma gangrenosum is a T cell-mediated disease targeting follicular adnexal structures: a hypothesis based on molecular and clinicopathologic studies","volume":"8","author":"Wang","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2024.09.023_bib179","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jid.2023.06.204","article-title":"NETosis Is Induced by complement component 5a: implications in the pathogenesis of Pyoderma gangrenosum","volume":"144","author":"Wang","year":"2024","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib180","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/j.1346-8138.2008.00572.x","article-title":"Leukocyte adsorption apheresis for the treatment of pyoderma gangrenosum","volume":"35","author":"Watanabe","year":"2008","journal-title":"J Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib181","series-title":"Weedon\u2019s skin pathology","author":"Weedon","year":"2010"},{"key":"10.1016\/j.jid.2024.09.023_bib182","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/01.ASW.0000744324.59877.df","article-title":"Peristomal pyoderma gangrenosum responding to risankizumab","volume":"34","author":"Weigelt","year":"2021","journal-title":"Adv Skin Wound Care"},{"key":"10.1016\/j.jid.2024.09.023_bib183","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4103\/JIPO.JIPO_11_18","article-title":"Pyoderma gangrenosum following initiation of immune checkpoint inhibitor therapy","volume":"1","author":"Welborn","year":"2018","journal-title":"J Immunother Precis Oncol"},{"key":"10.1016\/j.jid.2024.09.023_bib184","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1080\/09546634.2021.1937475","article-title":"Ustekinumab as adjuvant treatment for all pyoderma gangrenosum subtypes","volume":"33","author":"Westerdahl","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jid.2024.09.023_bib185","article-title":"Pyoderma gangrenosum induced by secukinumab-A late paradoxical drug reaction","volume":"33","author":"Wollina","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jid.2024.09.023_bib186","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/nm.3887","article-title":"Diabetes primes neutrophils to undergo NETosis, which impairs wound healing","volume":"21","author":"Wong","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.jid.2024.09.023_bib187","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/bjd.15193","article-title":"Drug-induced pyoderma gangrenosum: a model to understand the pathogenesis of pyoderma gangrenosum","volume":"177","author":"Wu","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib188","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jaad.2019.08.001","article-title":"Prevalence estimates for pyoderma gangrenosum in the United States: an age- and sex-adjusted population analysis","volume":"83","author":"Xu","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib189","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jid.2024.08.040","article-title":"IL-12\/IL23 blockade reveals patterns of asynchronous inflammation in pyoderma gangrenosum","volume":"145","author":"Yadav","year":"2025","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib190","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/1346-8138.15533","article-title":"Adalimumab in Japanese patients with active ulcers of pyoderma gangrenosum: twenty-six-week phase 3 open-label study","volume":"47","author":"Yamasaki","year":"2020","journal-title":"J Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib191","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/imr.12577","article-title":"Alarmins and immunity","volume":"280","author":"Yang","year":"2017","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jid.2024.09.023_bib192","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1038\/nm.2847","article-title":"Infection-induced NETosis is a dynamic process involving neutrophil multitasking in vivo","volume":"18","author":"Yipp","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.jid.2024.09.023_bib193","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1038\/cdd.2009.96","article-title":"Viable neutrophils release mitochondrial DNA to form neutrophil extracellular traps","volume":"16","author":"Yousefi","year":"2009","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.jid.2024.09.023_bib194","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3389\/fimmu.2016.00137","article-title":"NETosing neutrophils activate complement both on their own NETs and bacteria via alternative and non-alternative pathways","volume":"7","author":"Yuen","year":"2016","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2024.09.023_bib195","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1097\/MEG.0b013e32816e070b","article-title":"Pyoderma gangrenosum and exacerbation of psoriasis resulting from pegylated interferon alpha and ribavirin treatment of chronic hepatitis C","volume":"19","author":"Yurci","year":"2007","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jid.2024.09.023_bib196","doi-asserted-by":"crossref","DOI":"10.1111\/iwj.14357","article-title":"Hundreds of inconsistencies in the nomenclature of pyoderma gangrenosum: the need to harmonise terminology for phenotypes","volume":"21","author":"Zhao","year":"2024","journal-title":"Int Wound J"},{"key":"10.1016\/j.jid.2024.09.023_bib197","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jdin.2023.05.009","article-title":"Multilesional pyoderma gangrenosum is associated with longer healing times and higher rates of underlying comorbidities: a single-center prospective registry study","volume":"12","author":"Zhao","year":"2023","journal-title":"JAAD Int"},{"key":"10.1016\/j.jid.2024.09.023_bib198","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1001\/jamadermatol.2023.6066","article-title":"Deep vein thrombosis and healing outcomes in patients with pyoderma gangrenosum","volume":"160","author":"Zhao","year":"2024","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2024.09.023_bib199","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S0140-6736(11)61306-8","article-title":"Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden","volume":"379","author":"Z\u00f6ller","year":"2012","journal-title":"Lancet"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X24029609?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X24029609?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T01:39:26Z","timestamp":1780277966000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X24029609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":199,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0022202X24029609"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2024.09.023","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Insights into the Pathogenesis of Pyoderma Gangrenosum","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2024.09.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Society for Investigative Dermatology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}